$16.04
-3.0%BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
BIOA • NASDAQ
| BioAge Labs, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
REVENUE | ||||
9M | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||
(213K) | (0.0) | (0.0) | (0.0) | |
9M | 0.0 | 0.0 | 0.0 | |
OPERATING INCOME | ||||
(101.8M) | (78.2M) | (48.4M) | (40M) | |
(27.8M) | (19.2M) | (14.5M) | (9.4M) | |
(74M) | (59M) | (33.9M) | (30.5M) | |
-92.8M | -78.2M | -48.4M | -40M | |
PRE-TAX INCOME | ||||
(697K) | (2.4M) | (7.8M) | (241K) | |
12.4M | 7.3M | -5.4M | 224K | |
12.2M | 7.1M | -15.5M | 247K | |
-80.6M | -71.1M | -63.9M | -39.7M | |
NET INCOME | ||||
-80.6M | -71.1M | -63.9M | -39.7M |
BIOA - Filing history and reports
No SEC filings available for BIOA
Continue your BIOA research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.